HAART in treatment-experienced patients in the 21st century: The audacity of hope

Future Virology

Volumn 4, Issue 1, 2009, Pages 39-41

  Conway, Brian ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR; ENFUVIRTIDE; ETRAVIRINE; PLACEBO; RALTEGRAVIR;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID ANALYSIS; PATIENT CARE; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REPLICATION;

EID: 70349209354     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.4.1.39     Document Type: Article

References (8)

1. Steigbigel RT, Cooper DA, Kumar PN et al.: Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med. 359, 339-354 (2008).
2. Palella FJ Jr, Delaney KM, Moorman AC et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338, 853-860 (1998).
3. Reynes J, Arasteh K, Clotet B et al.: TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDS 21, 533-543 (2007).
4. Youle M, Staszweski S, Clotet B et al.: Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations. HIV Clin. Trials 7, 86-96 (2006).
5. Cooper DA, Steigbigel, RT, Gatell JM et al.: Subgroup and resistance analysis of raltegravir for resistant HIV-1 infection. N. Engl. J. Med. 359, 355-365 (2008).
6. Yazdanpanah Y, Fagard C, Descamps D et al.: High rate of virologic success with raltegravir plus-etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: results of the ANRS 139 TRIO trial. Program and Abstracts of the 17th International AIDS Conference. Mexico City, Mexico, 3-8 August, 2008 (Abstract THAB0406).
7. Gulick RM, Lalezari J, Goodrich J et al.: Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 359, 1429-1441 (2008).
8. Harris M, Larsen G, Montaner JSG: Exacerbation of depression associated with starting rakegravir: a report of four cases. AIDS 22, 1890-1892 (2008).